Metformin, rapamycin, aging, and cancer

Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer

During the last decade it was established that conservative growth hormone/ insulin-like growth factor-1 (IGF-1) and target of rapamycin (TOR) signaling pathways plays a key role in the control of aging and age-associated pathology in yeast, worms, insects and mammals [1-3]. […]

It was shown that the treated with antidiabetic biguanide metformin diabetes type 2 patients have from 25% to 40% less cancer than those who receive insulin as therapy or treated with sulfonylurea drugs that increase insulin secretion from the pancreas [1-3]. It was shown that biguanides like inhibitor of mTOR rapamycin prolong the lifespan of animals from yeast to mammals [2,3]. […]


Leave a Comment: